Company record
A clear public starting point.
This page gathers the company’s published description, taxonomy, status, and official link in one place. It does not make claims about private activity or deal terms.
Startup in Sahin’s portfolio

Latus Bio is developing curative AAV gene therapy products for CNS disorders
Latus Bio develops AAV gene therapies, engineering capsids and delivery routes so a therapy reaches the right cells in the right tissues. It focuses on diseases of the central nervous system and beyond.
Source: Latus Bio
P. Peter Ghoroghchian, an MD and PhD, is the CEO of Latus Bio.
Source: Latus Bio
Latus Bio works from offices and labs in Philadelphia and in Boston's Seaport district.
Source: Latus Bio
The company lists programs for CLN2 disease and Huntington's disease. It is also mining its own database of tissue delivery targets for other CNS and peripheral conditions.
Source: Latus Bio
As an angel investor in 231 startups across 14 categories, I look for companies with exceptional founders, large addressable markets, and clear competitive advantages. Latus Bio stood out in the Biotech space.
Company record
This page gathers the company’s published description, taxonomy, status, and official link in one place. It does not make claims about private activity or deal terms.